Ectoline spot on solution for cats
Country: Italja
Lingwa: Ingliż
Sors: HMA (Heads of Medicines Agencies)
Karatteristiċi tal-prodott
(SPC)
10-05-2013
Xi dokumenti għal dan il-prodott mhumiex disponibbli bħalissa, tista 'tibgħat talba lis-servizz tal-konsumatur tagħna u aħna ninnotifikawkom malli nkunu nistgħu niksbuhom.
Ibgħat talba.
Ibgħat talba.
Ingredjent attiv:
fipronil 100 mg
Disponibbli minn:
Alfamed
Kodiċi ATC:
QP53AX15
Għamla farmaċewtika:
Spot-on solution
Grupp terapewtiku:
fipronil
Żona terapewtika:
Cats
Data ta 'l-awtorizzazzjoni:
2012-01-31
Karatteristiċi tal-prodott
Revised: January 2012
AN: 01617/2011
Page 1 of 8
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
ALFAMED 50 mg spot-on solution for cats
(DE: FIPROLINE, FR: TICK-PUSS, IT: PROCARE FICONTROL, UK: ECTOLINE
50 mg spot-on solution for cats and Kittens over 8 weeks above 1kg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One 0.5 ml pipette contains :
ACTIVE SUBSTANCE:
Fipronil
50 mg
EXCIPIENTS:
Butylhydroxyanisole E320 0.1 mg/pipette
Butylhydroxytoluene E321 0.05 mg/pipette
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Spot-on solution.
Clear, colourless to yellow solution.
4.
CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats.
4.2 INDICATIONS FOR USE
Treatment of flea (_Ctenocephalides_ spp.) and tick (_Dermacentor reticulatus_)
infestations.
The product has a persistent insecticidal efficacy for up to 5 weeks against fleas
(_Ctenocephalides_ _felis_).
The product has a persistent acaricidal efficacy for up to 2 weeks against ticks
(_Rhipicephalus sanguineus, Ixodes ricinus,_ _Dermacentor reticulatus_). If ticks of
some species (_Rhipicephalus sanguineus_ and _Ixodes ricinus_) are present when
the product is applied, all the ticks may not be killed within the first 48 hours but
they may be killed within a week.
The product can be used as part of a treatment strategy for the control of Flea
Allergy Dermatitis (FAD) where this has been previously diagnosed by a veterinary
surgeon.
Revised: January 2012
AN: 01617/2011
Page 2 of 8
Revised: January 2012
AN: 01617/2011
Page 3 of 8
4.3 CONTRAINDICATIONS
In the absence of available data,
Aqra d-dokument sħiħ
